Evidence map›Paper›PMID 30062829›Full record

ArticleChembiochem : a European journal of chemical biology2018

A Versatile and Convenient Synthesis of

Rouven Stulz, Johan Meuller, Dženita Baždarević, Charlotte Wennberg Huldt, Roger Strömberg, Shalini Andersson, Anders Dahlén

Open access · hybridAbstract read
In one paragraph

Article in Chembiochem : a European journal of chemical biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. A Versatile and Convenient Synthesis ofChembiochem : a European journal of chemical biology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Rouven StulzCardiovascular, Renal and Metabolism IMED Biotech Unit, AstraZeneca, Pepparedsleden 1, 43150, Mölndal, Sweden.
Johan MeullerDiscovery Sciences IMED Biotech Unit, AstraZeneca, Pepparedsleden 1, 43150, Mölndal, Sweden.
Dženita BaždarevićCardiovascular, Renal and Metabolism IMED Biotech Unit, AstraZeneca, Pepparedsleden 1, 43150, Mölndal, Sweden.
Charlotte Wennberg HuldtCardiovascular, Renal and Metabolism IMED Biotech Unit, AstraZeneca, Pepparedsleden 1, 43150, Mölndal, Sweden.
Roger StrömbergDepartment of Biosciences and Nutrition, Karolinska Institutet, NEO, Hälsovägen 9, 14157, Huddinge, Sweden.
Shalini AnderssonCardiovascular, Renal and Metabolism IMED Biotech Unit, AstraZeneca, Pepparedsleden 1, 43150, Mölndal, Sweden.
Anders DahlénCardiovascular, Renal and Metabolism IMED Biotech Unit, AstraZeneca, Pepparedsleden 1, 43150, Mölndal, Sweden.ORCID 0000-0002-2641-7918
AstraZeneca (Sweden) · SEKarolinska Institutet · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A synthetic protocol for

Indexed as

Oligonucleotides, AntisensePhenylacetatesPhosphorothioate OligonucleotidesSulfidesGlucagon-Like Peptide-1 ReceptorHEK293 CellsHumansIsotope LabelingRNA, Long NoncodingSulfurGLP1R protein, humanGlucagon-Like Peptide-1 ReceptorMALAT1 long non-coding RNA, humanOligonucleotides, AntisensePhenylacetatesphenylacetyl disulfidePhosphorothioate OligonucleotidesRNA, Long NoncodingSulfidesSulfurantisense agentsisotopic labelingoligonucleotidessulfursynthesis design

Identifiers

PMID30062829
PMCPMC6585993
OpenAlexW2887204076

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.